Inden Revatio markedsføres i medlemsstaterne, skal virksomheden, der fremstiller lægemidlet sende et brev til sundhedsmedarbejdere om, at det ikke må indtages sammen med nitrater.
Before Revatio is launched in each Member State, the company that makes the medicine will send a letter to healthcare workers explaining that it must not be taken with nitrates.